Iovance Biotherapeutics (IOVA) Q2 FY26 earnings call

Iovance Biotherapeutics delivered a robust second quarter, driven by record revenue and expanding gross margins, primarily from strong Ampagni demand. The company is advancing its clinical pipeline with key regulatory designations and trial progress, while also managing operating expenses effectively. Management is reviewing its full-year revenue guidance, anticipating an upward revision in the third quarter, reflecting confidence in continued commercial momentum and operational discipline.